153 related articles for article (PubMed ID: 5136462)
1. Passage into the rat brain of dopa and dopamine injected into the lateral ventricle.
Constantinidis J; Gaillard JM; Geissbuhler F; Tissot R
Br J Pharmacol; 1971 Sep; 43(1):32-8. PubMed ID: 5136462
[TBL] [Abstract][Full Text] [Related]
2. A rapid fluorescence microscopic method for the study of the capillary DOPA-dopamine barrier.
Jancsó G
J Neurochem; 1975 Mar; 24(3):579-80. PubMed ID: 1113128
[No Abstract] [Full Text] [Related]
3. Effects of reserpine and prenylamine on the L-dopa turnover in the rat exocrine pancreas.
Alm P; Ehinger B; Falck B; Nordgren L
Eur J Pharmacol; 1971 Oct; 16(2):192-200. PubMed ID: 5161258
[No Abstract] [Full Text] [Related]
4. Dopamine: mediator of brain polysome disaggregation after L-dopa.
Weiss BF; Munro HN; Ordonez LA; Wurtman RJ
Science; 1972 Aug; 177(4049):613-6. PubMed ID: 4403139
[TBL] [Abstract][Full Text] [Related]
5. [The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat].
Constantinidis J; Bartholini G; Geissbühler F; Tissot R
Experientia; 1970 Apr; 26(4):381-3. PubMed ID: 5439606
[No Abstract] [Full Text] [Related]
6. Effect of dopamine-beta-hydroxylase inhibitors 1,1-dimethyl-3-phenyl-2-thiourea, fusaric acid and dimethyldithiocarbamate, on the rat brain monoamine content following intraventricular injection of L-dopa.
Vetulani J; Reichenberg K
Biochem Pharmacol; 1973 Jun; 22(11):1263-8. PubMed ID: 4727781
[No Abstract] [Full Text] [Related]
7. L-Dopa and imipramine: biochemical and behavioral interaction.
Friedman E; Gershon S
Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
[No Abstract] [Full Text] [Related]
8. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs.
Furuta Y; Hashimoto K; Iwatsuki K; Takeuchi O
Br J Pharmacol; 1973 Jan; 47(1):77-84. PubMed ID: 4717022
[TBL] [Abstract][Full Text] [Related]
9. On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
Pfeiffer R; Ebadi M
J Neurochem; 1972 Sep; 19(9):2175-81. PubMed ID: 5072392
[No Abstract] [Full Text] [Related]
10. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase.
Seiden LS; Martin TW
Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757
[No Abstract] [Full Text] [Related]
11. Relative penetration of L-dopa and 5-HTP through the brain barrier using dimethyl sulfoxide.
De la Torre JC
Experientia; 1970 Oct; 26(10):1117-8. PubMed ID: 5312418
[No Abstract] [Full Text] [Related]
12. Monoamine oxidase and cerebral uptake of dopaminergic drugs.
Cotzias GC; Tang LC; Ginos JZ
Proc Natl Acad Sci U S A; 1974 Jul; 71(7):2715-9. PubMed ID: 4137067
[TBL] [Abstract][Full Text] [Related]
13. Effects of pilocarpine on L-dopa turnover in the exocrine rat pancreas.
Alm P
Acta Physiol Scand; 1971 Oct; 83(2):269-77. PubMed ID: 5114364
[No Abstract] [Full Text] [Related]
14. Mechanism of release of alpha-methylated noradrenaline analogues by monoamine oxidase inhibitors.
Carlsson A; Lindqvist M; Waldeck B
Eur J Pharmacol; 1968 Apr; 3(1):34-9. PubMed ID: 5654667
[No Abstract] [Full Text] [Related]
15. Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain.
Constantinidis J; Bartholini G; Tissot R; Pletscher A
Experientia; 1968 Feb; 24(2):130-1. PubMed ID: 5643797
[No Abstract] [Full Text] [Related]
16. Dopamine formation in brain capillaries--an enzymic blood-brain barrier mechanism.
Owman C; Rosengren E
J Neurochem; 1967 May; 14(5):547-50. PubMed ID: 6025622
[No Abstract] [Full Text] [Related]
17. Extraneuronal binding of catecholamines and 3,4-dihydroxyphenylalanine (dopa) in salivary glands.
Hamberger B; Norberg KA; Olson L
Acta Physiol Scand; 1967; 69(1):1-12. PubMed ID: 5340156
[No Abstract] [Full Text] [Related]
18. Aromatic amino acid decarboxylase inhibitors.
Porter CC
Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
[No Abstract] [Full Text] [Related]
19. Carbidopa attenuation of L-DOPA emesis in dogs: evidence for a cerebral site of action outside the blood-brain barrier.
Lotti VJ; Clark C
Eur J Pharmacol; 1974 Mar; 25(3):322-5. PubMed ID: 4827858
[No Abstract] [Full Text] [Related]
20. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
[No Abstract] [Full Text] [Related]
[Next] [New Search]
